This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 i…

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

~Estimated

~$10 – $8,750

Iambic Therapeutics, IncNCT06253871

Phase 1

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung Cancer+3 more

~Estimated

~$10 – $8,750

Mersana TherapeuticsNCT05514717